Liz Toapanta-Yanchapaxi
Research Subjects
Research Interests
Liz Toapanta-Yanchapaxi has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Erwin Chiquete
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
9 shared publications - Alan Gabriel Contreras
Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Mexico
4 shared publications - Carlos Cantú-Brito
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
4 shared publications - Ignacio García-Juárez
Departamento de Gastroenterología y Hepatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico
4 shared publications - Ana Ochoa-Guzmán
Unidad de Biología Molecular y Medicina Genómica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City 14080, Mexico
3 shared publications - Eduardo Ruiz-Ruiz
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, CDMX, México
3 shared publications
Latest Publications
- Open Access
Multinational attitudes towards AI in healthcare and diagnostics among hospital patients
The successful implementation of artificial intelligence (AI) in healthcare is dependent upon the acceptance of this technology by key stakeholders, particularly patients, who are the primary beneficiaries of AI-driven outcomes. This international, multicenter, cross-sectional study assessed the attitudes of hospital patients towards AI in healthcare across 43 countries. A total of 13806 patients at 74 hospitals were surveyed between February and November 2023, with 64.8% from the Global North and 35.2% from the Global South. The findings indicate a predominantly favorable general view of AI in healthcare, with 57.6% of respondents expressing a positive attitude. However, attitudes exhibited notable variation based on demographic characteristics, health status, and technological literacy. Female respondents and those with poorer health status exhibited fewer positive attitudes towards AI use in medicine. Conversely, higher levels of AI knowledge and frequent use of technology devices were associated with more positive attitudes. It is noteworthy that less than half of the participants expressed positive attitudes regarding all items pertaining to trust in AI. The lowest level of trust was observed for the accuracy of AI in providing information regarding treatment responses. Patients exhibited a strong preference for explainable AI and physician-led decision-making, even if it meant slightly compromised accuracy. This large-scale, multinational study provides a comprehensive perspective on patient attitudes towards AI in healthcare across six continents. Findings suggest a need for tailored AI implementation strategies that consider patient demographics, health status, and preferences for explainable AI and physician oversight. All study data has been made publicly available to encourage replication and further investigation.
Open AccessMultinational attitudes towards AI in healthcare and diagnostics among hospital patients
The successful implementation of artificial intelligence (AI) in healthcare is dependent upon the acceptance of this technology by key stakeholders, particularly patients, who are the primary beneficiaries of AI-driven outcomes. This international, multicenter, cross-sectional study assessed the attitudes of hospital patients towards AI in healthcare across 43 countries. A total of 13806 patients at 74 hospitals were surveyed between February and November 2023, with 64.8% from the Global North and 35.2% from the Global South. The findings indicate a predominantly favorable general view of AI in healthcare, with 57.6% of respondents expressing a positive attitude. However, attitudes exhibited notable variation based on demographic characteristics, health status, and technological literacy. Female respondents and those with poorer health status exhibited fewer positive attitudes towards AI use in medicine. Conversely, higher levels of AI knowledge and frequent use of technology devices were associated with more positive attitudes. It is noteworthy that less than half of the participants expressed positive attitudes regarding all items pertaining to trust in AI. The lowest level of trust was observed for the accuracy of AI in providing information regarding treatment responses. Patients exhibited a strong preference for explainable AI and physician-led decision-making, even if it meant slightly compromised accuracy. This large-scale, multinational study provides a comprehensive perspective on patient attitudes towards AI in healthcare across six continents. Findings suggest a need for tailored AI implementation strategies that consider patient demographics, health status, and preferences for explainable AI and physician oversight. All study data has been made publicly available to encourage replication and further investigation.
- Open Access
Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2
Background: Despite the high number of vaccines administered against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, the information on the psychological/psychiatric adverse events following immunization (AEFI) with these newly developed vaccines remains scarce. Objective: To describe the frequency of psychological/psychiatric symptoms among recipients of five different anti-SARS-CoV-2 vaccines and to explore the factors associated with their development reported in the nationwide Mexican registry of AEFI against SARS-CoV-2. Methods: Descriptive study of all the psychological/psychiatric symptoms, including anxiety, panic attacks, insomnia, and agitation reported to the Mexican Epidemiological Surveillance System from 21 December 2020 to 27 April 2021, among adult (≥18 years old) recipients of 7,812,845 doses of BNT162b2, ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, or CoronaVac. The factors associated with their development are determined by multivariate regression analysis. Results: There were 19,163 AEFI reports during the study period; amongst them, 191 (1%) patients had psychological/psychiatric symptoms (median age of 41 years, interquartile range of 32–54; 149 [78%] women) for an observed incidence of 2.44 cases per 100,000 administered doses (95% confidence interval [CI] 2.12–2.82), 72.8% of psychiatric AEFIs were reported among recipients of BNT162b2. The median time from vaccination to symptom onset was 35 min (interquartile range: 10–720). Overall, the most common psychological/psychiatric symptoms were anxiety in 129 (67.5%) patients, panic attacks in 30 (15.7%), insomnia in 25 (13%), and agitation in 11 (5.7%). After adjusting for the confounding factors, the odds for developing psychological/psychiatric symptoms were higher for those concurrently reporting syncope (odds ratio [OR]: 4.73, 95% CI: 1.68–13.33); palpitations (OR: 2.47, 95% CI: 1.65–3.70), and dizziness (OR: 1.59, 95% CI: 1.10–2.28). Conclusion: In our population, psychological/psychiatric symptoms were extremely infrequent AEFIs. No severe psychiatric AEFIs were reported. Immunization stress-related responses might explain most of the detected cases.
Open AccessPsychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2
Background: Despite the high number of vaccines administered against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, the information on the psychological/psychiatric adverse events following immunization (AEFI) with these newly developed vaccines remains scarce. Objective: To describe the frequency of psychological/psychiatric symptoms among recipients of five different anti-SARS-CoV-2 vaccines and to explore the factors associated with their development reported in the nationwide Mexican registry of AEFI against SARS-CoV-2. Methods: Descriptive study of all the psychological/psychiatric symptoms, including anxiety, panic attacks, insomnia, and agitation reported to the Mexican Epidemiological Surveillance System from 21 December 2020 to 27 April 2021, among adult (≥18 years old) recipients of 7,812,845 doses of BNT162b2, ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, or CoronaVac. The factors associated with their development are determined by multivariate regression analysis. Results: There were 19,163 AEFI reports during the study period; amongst them, 191 (1%) patients had psychological/psychiatric symptoms (median age of 41 years, interquartile range of 32–54; 149 [78%] women) for an observed incidence of 2.44 cases per 100,000 administered doses (95% confidence interval [CI] 2.12–2.82), 72.8% of psychiatric AEFIs were reported among recipients of BNT162b2. The median time from vaccination to symptom onset was 35 min (interquartile range: 10–720). Overall, the most common psychological/psychiatric symptoms were anxiety in 129 (67.5%) patients, panic attacks in 30 (15.7%), insomnia in 25 (13%), and agitation in 11 (5.7%). After adjusting for the confounding factors, the odds for developing psychological/psychiatric symptoms were higher for those concurrently reporting syncope (odds ratio [OR]: 4.73, 95% CI: 1.68–13.33); palpitations (OR: 2.47, 95% CI: 1.65–3.70), and dizziness (OR: 1.59, 95% CI: 1.10–2.28). Conclusion: In our population, psychological/psychiatric symptoms were extremely infrequent AEFIs. No severe psychiatric AEFIs were reported. Immunization stress-related responses might explain most of the detected cases.
- 5 March 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (2) , 627-629
A young man with vertical diplopia and Bielschowsky sign: isotretinoin-induced extraocular myopathy
- 5 March 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (2) , 627-629
A young man with vertical diplopia and Bielschowsky sign: isotretinoin-induced extraocular myopathy
- Open Access
- 1 January 2022
- Published by GRAPHIMEDIC SA DE CV in Revista Mexicana de Trasplantes
- Vol. 11 (1) , 25-34
Propuesta de algoritmo para asignación de injertos renales en población mexicana: injerto único o dual acorde a criterios del donador
- 1 January 2022
- Published by GRAPHIMEDIC SA DE CV in Revista Mexicana de Trasplantes
- Vol. 11 (1) , 25-34
Open AccessPropuesta de algoritmo para asignación de injertos renales en población mexicana: injerto único o dual acorde a criterios del donador
- Open Access
- 1 January 2022
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 63 (1) , 3-13
Delirium and Associated Factors in a Cohort of Hospitalized Patients With Coronavirus Disease 2019
- 1 January 2022
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 63 (1) , 3-13
Open AccessDelirium and Associated Factors in a Cohort of Hospitalized Patients With Coronavirus Disease 2019
- 1 October 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (7) , 713-718
Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
- 1 October 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (7) , 713-718
Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
- 1 September 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (7) , 2346-2353
Bone Disease and Liver Transplantation: A Review
- 1 September 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (7) , 2346-2353
Bone Disease and Liver Transplantation: A Review
- Open Access
- 4 December 2020
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 18 (3) , 711-718
Ethnicity and other COVID-19 death risk factors in Mexico
Introduction: Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may develop coronavirus disease 2019 (COVID-19). Risk factors associated with death vary among countries with different ethnic backgrounds. We aimed to describe the factors associated with death in Mexicans with confirmed COVID-19.Material and methods: We analysed the Mexican Ministry of Health’s official database on people tested for SARS-CoV-2 infection by real-time reverse transcriptase–polymerase chain reaction (rtRT-PCR) of nasopharyngeal fluids. Bivariate analyses were performed to select characteristics potentially associated with death, to integrate a Cox-proportional hazards model.Results: As of May 18, 2020, a total of 177,133 persons (90,586 men and 86,551 women) in Mexico received rtRT-PCR testing for SARS-CoV-2. There were 5332 deaths among the 51,633 rtRT-PCR-confirmed cases (10.33%, 95% CI: 10.07–10.59%). The median time (interquartile range, IQR) from symptoms onset to death was nine days (5–13 days), and from hospital admission to death 4 days (2–8 days). The analysis by age groups revealed that the significant risk of death started gradually at the age of 40 years. Independent death risk factors were obesity, hypertension, male sex, indigenous ethnicity, diabetes, chronic kidney disease, immunosuppression, chronic obstructive pulmonary disease, age > 40 years, and the need for invasive mechanical ventilation (IMV). Only 1959 (3.8%) cases received IVM, of whom 1893 were admitted to the intensive care unit (96.6% of those who received IMV).Conclusions: In Mexico, highly prevalent chronic diseases are risk factors for death among persons with COVID-19. Indigenous ethnicity is a poorly studied factor that needs more investigation.
- 4 December 2020
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 18 (3) , 711-718
Open AccessEthnicity and other COVID-19 death risk factors in Mexico
Introduction: Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may develop coronavirus disease 2019 (COVID-19). Risk factors associated with death vary among countries with different ethnic backgrounds. We aimed to describe the factors associated with death in Mexicans with confirmed COVID-19.Material and methods: We analysed the Mexican Ministry of Health’s official database on people tested for SARS-CoV-2 infection by real-time reverse transcriptase–polymerase chain reaction (rtRT-PCR) of nasopharyngeal fluids. Bivariate analyses were performed to select characteristics potentially associated with death, to integrate a Cox-proportional hazards model.Results: As of May 18, 2020, a total of 177,133 persons (90,586 men and 86,551 women) in Mexico received rtRT-PCR testing for SARS-CoV-2. There were 5332 deaths among the 51,633 rtRT-PCR-confirmed cases (10.33%, 95% CI: 10.07–10.59%). The median time (interquartile range, IQR) from symptoms onset to death was nine days (5–13 days), and from hospital admission to death 4 days (2–8 days). The analysis by age groups revealed that the significant risk of death started gradually at the age of 40 years. Independent death risk factors were obesity, hypertension, male sex, indigenous ethnicity, diabetes, chronic kidney disease, immunosuppression, chronic obstructive pulmonary disease, age > 40 years, and the need for invasive mechanical ventilation (IMV). Only 1959 (3.8%) cases received IVM, of whom 1893 were admitted to the intensive care unit (96.6% of those who received IMV).Conclusions: In Mexico, highly prevalent chronic diseases are risk factors for death among persons with COVID-19. Indigenous ethnicity is a poorly studied factor that needs more investigation.
- Open Access
Methods of An Open-Label Proof-Of-Concept Trial of Intravenous Valproic Acid for Severe COVID-19
Introduction: Coronavirus disease 2019 (COVID-19) is the systemic entity caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause death through severe atypical pneumonia and acute lung injury. Valproic acid (VPA) has shown anti-inflammatory activity and mild intrinsic antiviral effect. These properties warrant the study of VPA as a possible active treatment in persons with severe COVID-19. Methods: Consecutive adult patients needing invasive mechanical ventilation (IMV) will be given intravenous (i.v.) VPA at a starting dose of 20 mg/kg/day and up to 60/kg/day (in 60 min i.v. infusions in 250 mL normal saline) as needed to reach plasma VPA concentrations of 50–100 μg/mL (measured every 72 h). These patients will be followed-up for 10 days for the primary outcome and for a further period of 30 days after treatment completion for the secondary outcome of recurrence. The primary study outcome is the reduction in the case fatality rate of at least 50% after 10 days of treatment (as compared with natural history). Secondary outcomes are the reduction of length of stay (LOS) of at least 50%, as well as COVID-19 recurrence at 30-day follow-up. The most important safety outcomes are acute liver failure, acute pancreatitis, and thrombocytopenia. Conclusion: Although long-term adverse effects and even pro-inflammatory consequences have been reported with the chronic use of VPA, given the urgent need for a drug against COVID-19 to shorten the high mortality and LOS, the study of VPA is justified from a scientific standpoint.
Open AccessMethods of An Open-Label Proof-Of-Concept Trial of Intravenous Valproic Acid for Severe COVID-19
Introduction: Coronavirus disease 2019 (COVID-19) is the systemic entity caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause death through severe atypical pneumonia and acute lung injury. Valproic acid (VPA) has shown anti-inflammatory activity and mild intrinsic antiviral effect. These properties warrant the study of VPA as a possible active treatment in persons with severe COVID-19. Methods: Consecutive adult patients needing invasive mechanical ventilation (IMV) will be given intravenous (i.v.) VPA at a starting dose of 20 mg/kg/day and up to 60/kg/day (in 60 min i.v. infusions in 250 mL normal saline) as needed to reach plasma VPA concentrations of 50–100 μg/mL (measured every 72 h). These patients will be followed-up for 10 days for the primary outcome and for a further period of 30 days after treatment completion for the secondary outcome of recurrence. The primary study outcome is the reduction in the case fatality rate of at least 50% after 10 days of treatment (as compared with natural history). Secondary outcomes are the reduction of length of stay (LOS) of at least 50%, as well as COVID-19 recurrence at 30-day follow-up. The most important safety outcomes are acute liver failure, acute pancreatitis, and thrombocytopenia. Conclusion: Although long-term adverse effects and even pro-inflammatory consequences have been reported with the chronic use of VPA, given the urgent need for a drug against COVID-19 to shorten the high mortality and LOS, the study of VPA is justified from a scientific standpoint.
- Open Access
- 30 January 2020
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 2 (2) , 44-48
Methods of An Open - Label Proof - of - Concept Trial of Intravenous Valproic Acid for Severe COVID-19
Introduction. Coronavirus disease 2019 (COVID-19) is the systemic entity caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause death through severe atypical pneumonia and acute lung injury. Valproic acid (VPA) has shown anti-inflammatory activity and intrinsic antiviral effect. These properties warrant the study of VPA as a possible active treatment in people with severe COVID-19. Material and Methods. Consecutive adult patients needing invasive mechanical ventilation (IMV) will be given intravenous (IV) VPA at a starting dose of 20 mg/kg/day and up to 60/kg/day (in 60 min IV infusions in 250 mL normal saline) as needed to reach plasma VPA concentrations of 50-100 μg/mL (measured every 72 h). These patients will be followed-up for 10 days for the primary outcome and for a further period of 30 days after treatment completion for the secondary outcome of recurrence. The primary study outcome is the reduction in the case fatality rate (CFR) of at least 50 % after 10 days of treatment (as compared with natural history). Secondary outcomes are the reduction of length of stay (LOS) of at least 50 %, as well as COVID-19 recurrence at 30-day follow-up. The most important safety outcomes are acute liver failure, acute pancreatitis, and thrombocytopenia. Conclusions. Although long-term adverse effects and even pro-inflammatory consequences have been reported with the chronic use of VPA, the study of VPA is justified from a scientific standpoint given the urgent need for a drug against COVID-19 to shorten the high mortality and LOS.
- 30 January 2020
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 2 (2) , 44-48
Open AccessMethods of An Open - Label Proof - of - Concept Trial of Intravenous Valproic Acid for Severe COVID-19
Introduction. Coronavirus disease 2019 (COVID-19) is the systemic entity caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause death through severe atypical pneumonia and acute lung injury. Valproic acid (VPA) has shown anti-inflammatory activity and intrinsic antiviral effect. These properties warrant the study of VPA as a possible active treatment in people with severe COVID-19. Material and Methods. Consecutive adult patients needing invasive mechanical ventilation (IMV) will be given intravenous (IV) VPA at a starting dose of 20 mg/kg/day and up to 60/kg/day (in 60 min IV infusions in 250 mL normal saline) as needed to reach plasma VPA concentrations of 50-100 μg/mL (measured every 72 h). These patients will be followed-up for 10 days for the primary outcome and for a further period of 30 days after treatment completion for the secondary outcome of recurrence. The primary study outcome is the reduction in the case fatality rate (CFR) of at least 50 % after 10 days of treatment (as compared with natural history). Secondary outcomes are the reduction of length of stay (LOS) of at least 50 %, as well as COVID-19 recurrence at 30-day follow-up. The most important safety outcomes are acute liver failure, acute pancreatitis, and thrombocytopenia. Conclusions. Although long-term adverse effects and even pro-inflammatory consequences have been reported with the chronic use of VPA, the study of VPA is justified from a scientific standpoint given the urgent need for a drug against COVID-19 to shorten the high mortality and LOS.